Positron Corporation (POSC)

[JackStraw]

Positron Announces PosiRx Program for a Total Solution in Cardiac Nuclear Medicine
Thursday January 8, 3:42 pm ET


HOUSTON--(BUSINESS WIRE)--Positron Corporation (OTCBB:POSC - News) announced today that they will market its complete turnkey offering of radiopharmaceuticals, camera service and imaging for a total solution to customers under the name PosiRx™. Positron’s PosiRx™ will offer financing and partnership flexibility by providing imaging providers the choice of radiopharmaceuticals, radiopharmaceutical dispensing systems, molecular imaging devices, and equipment service directly from Positron. Customers can choose all services as a complete package or individual parts that suit their needs. Positron is able to offer innovative distribution and dose dispensing of radiopharmaceuticals directly to imaging providers as a result of their cutting edge “virtual pharmacy” device named the Nuclear Pharm-Assist®.
Positron’s President, Joseph Oliverio stated, “We are addressing the needs of physicians in these challenging economic times by providing them with patient and business flexibility combined with cost effective imaging provision alternatives.” Oliverio also went on to state, “that our new PosiRx™ solution will set a new industry standard for the distribution of radiopharmaceuticals giving Positron a significant market share in the massive radiopharmaceutical and imaging device market.”

About Positron

Positron Corporation is a vertically integrated company in the field of Cardiac Nuclear Medicine. The Company operates through two segments: Molecular Imaging Devices and Radiopharmaceutical Products. The Molecular Imaging Devices segment provides Positron Emission Tomography (PET) scanners and Single Photon Emission Computed Tomography (SPECT) cameras; the Radiopharmaceutical Products segment offers world’s first robotic systems for distribution and delivery of radiopharmaceuticals and provides radiopharmaceutical agents used for the diagnosis of cardiac diseases. The Company is able to offer a total customer solution which includes molecular imaging devices, disease specific software, radiopharmaceutical distribution and delivery systems, and radiopharmaceuticals agents for Cardiac Nuclear Medicine. Positron Corporation was incorporated in 1983 and is currently headquartered in Houston, Texas. Positron’s SPECT and PET cardiac molecular imaging systems and radiopharmaceutical deliver devices are installed in more than 150 hospitals and physician offices around the world. Additional information may be found at http://www.positron.com.

Forward Looking Statements:

Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. The words “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “estimate,” and similar expressions are intended to identify such forward-looking statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.

For further information please contact Positron Corporation at [phone].